Superior Survival With Sintilimab in Squamous NSCLC Superior Survival With Sintilimab in Squamous NSCLC
Second-line treatment with sintilimab improved survival compared with docetaxel in patients with advanced/metastatic squamous nonsmall cell lung cancer in the phase 3 ORIENT-3 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Taxotere